全文获取类型
收费全文 | 1420篇 |
免费 | 119篇 |
国内免费 | 31篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 67篇 |
妇产科学 | 11篇 |
基础医学 | 210篇 |
口腔科学 | 39篇 |
临床医学 | 182篇 |
内科学 | 320篇 |
皮肤病学 | 21篇 |
神经病学 | 95篇 |
特种医学 | 68篇 |
外科学 | 164篇 |
综合类 | 46篇 |
预防医学 | 71篇 |
眼科学 | 36篇 |
药学 | 102篇 |
中国医学 | 1篇 |
肿瘤学 | 124篇 |
出版年
2023年 | 6篇 |
2022年 | 17篇 |
2021年 | 41篇 |
2020年 | 20篇 |
2019年 | 30篇 |
2018年 | 33篇 |
2017年 | 38篇 |
2016年 | 36篇 |
2015年 | 27篇 |
2014年 | 47篇 |
2013年 | 49篇 |
2012年 | 67篇 |
2011年 | 78篇 |
2010年 | 47篇 |
2009年 | 47篇 |
2008年 | 55篇 |
2007年 | 60篇 |
2006年 | 77篇 |
2005年 | 67篇 |
2004年 | 75篇 |
2003年 | 48篇 |
2002年 | 43篇 |
2001年 | 45篇 |
2000年 | 34篇 |
1999年 | 43篇 |
1998年 | 29篇 |
1997年 | 27篇 |
1996年 | 23篇 |
1995年 | 19篇 |
1994年 | 15篇 |
1993年 | 9篇 |
1992年 | 26篇 |
1991年 | 18篇 |
1990年 | 21篇 |
1989年 | 24篇 |
1988年 | 24篇 |
1987年 | 23篇 |
1986年 | 32篇 |
1985年 | 22篇 |
1984年 | 15篇 |
1983年 | 10篇 |
1982年 | 9篇 |
1981年 | 9篇 |
1980年 | 6篇 |
1979年 | 14篇 |
1978年 | 8篇 |
1977年 | 7篇 |
1976年 | 7篇 |
1975年 | 8篇 |
1967年 | 5篇 |
排序方式: 共有1570条查询结果,搜索用时 12 毫秒
31.
Ranjana Advani George A Fisher Bert L Lum Charro Jambalos Cheryl D Cho Marvin Cohen Ashwin Gollerkeri Branimir I Sikic 《Clinical cancer research》2003,9(14):5187-5194
PURPOSE: The purpose of this study was to establish the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and preliminary activity of BMS-188797 administered weekly. EXPERIMENTAL DESIGN: Patients with advanced malignancies were treated with escalating doses of BMS-188797 on a weekly schedule as a 1-h i.v. infusion. Plasma sampling was performed to characterize the pharmacokinetics of BMS-188797. RESULTS: Eighteen patients with advanced malignancies were enrolled at three dose levels ranging from 35 to 65 mg/m(2). The number of patients evaluated at each dose level was as follows: 35 mg/m(2) (n = 3); 50 mg/m(2) (n = 9); and 65 mg/m(2) (n = 6). At 65 mg/m(2), three of six patients had a DLT (one had grade 4 neutropenia lasting >7 days, and two had grade 3 diarrhea). Expansion of the 50-mg/m(2) dose cohort to nine patients established this dose as the MTD, with one patient experiencing a DLT (grade 4 neutropenia with fever). Two partial responses were observed (lung cancer, 7+ months; ovarian cancer, 6+ months durations), as well as two minor responses (esophageal cancer, 5 months; ovarian cancer, 5 months). Both patients with partial responses had been clinically resistant to paclitaxel. Plasma pharmacokinetic mean values of maximum concentration (C(max)) and area under the curve (AUC(0-48)) increased in a dose-dependent manner within the range of doses used in this study, and in three of four patients, the DLTs correlated with AUC. CONCLUSIONS: The MTD and the recommended Phase II dose of weekly BMS-188797 is 50 mg/m(2). The drug demonstrates antitumor activity in taxane-refractory solid tumors and is now being evaluated in combination with carboplatin. 相似文献
32.
Dibenzo[a,l]pyrene-induced DNA adduction, tumorigenicity, and Ki-ras oncogene mutations in strain A/J mouse lung 总被引:1,自引:0,他引:1
Prahalad AK; Ross JA; Nelson GB; Roop BC; King LC; Nesnow S; Mass MJ 《Carcinogenesis》1997,18(10):1955-1963
Dibenzo[a,l]pyrene (DB[a,l]P), an environmental polycyclic aromatic
hydrocarbon, is the most potent carcinogen ever tested in mouse skin and
rat mammary gland. In this study, DB[a,l]P was examined for DNA adduction,
tumorigenicity, and induction of Ki-ras oncogene mutations in tumor DNA in
strain A/J mouse lung. Groups of mice received a single i.p. injection of
0.3, 1.5, 3.0, or 6.0 mg/kg DB[a,l]P in tricaprylin. Following treatment,
DNA adducts were measured at times between 1 and 28 days, while tumors were
counted at 250 days and analyzed for the occurrence of point mutations in
codons 12 and 61 of the Ki-ras oncogene. DB[a,l]P in strain A/J mouse lung
induced six major and four minor DNA adducts. Maximal levels of adduction
occurred between 5 and 10 days after injection followed by a gradual
decrease. DB[a,l]P-DNA adducts in lung tissue were derived from both anti-
and syn-11,12- dihydroxy-13,14-epoxy-
11,12,13,14-tetrahydrodibenzo[a,l]pyrene (DB[a,l]PDE) and both
deoxyadenosine (dAdo) and deoxyguanosine (dGuo) residues in DNA as revealed
by cochromatography. The major adduct was identified as a product of the
reaction of an anti-DB[a,l]PDE with dAdo in DNA. DB[a,l]P induced
significant numbers of lung adenomas in a dose- dependent manner, with the
highest dose (6.0 mg/kg) yielding 16.1 adenomas/mouse. In
tricaprylin-treated control animals, there were 0.67 adenomas/mouse. Based
on the administered dose, DB[a,l]P was more active than other environmental
carcinogens including benzo[a]pyrene. As a function of time-integrated DNA
adduct levels, DB[a,l]P induced lung adenomas with about the same potency
as other PAHs, suggesting that the adducts formed by DB[a,l]P are similar
in carcinogenic potency to other PAHs in the strain A/J mouse lung model.
Analysis of the Ki- ras mutation spectrum in DB[a,l]P-induced lung tumors
revealed the predominant mutations to be G-->T transversions in the
first base of codon 12, A-->G transitions in the second base of codon
12, and A-->T transversions in the second or third base of codon 61,
concordant with the DNA adduct profile.
相似文献
33.
Nesnow S; Davis C; Nelson G; Ross JA; Allison J; Adams L; King LC 《Carcinogenesis》1997,18(10):1973-1978
C3H10T1/2CL8 (C3H10T1/2) mouse embryo fibroblasts were used to study the in
vitro carcinogenic activities of dibenzo[a,l]pyrene (DB[a,l]P) and
benzo[a]pyrene (B[a]P). The morphological transforming activities of these
rodent carcinogens were compared using replicate concentration- response
studies. In concentration ranges where both polycyclic aromatic
hydrocarbons (PAHs) were active, DB[a,l]P proved to be four to 12 times as
potent as B[a]P based on concentration. At lower concentrations DB[a,l]P
was active at 0.10 and 0.20 microM, concentrations where B[a]P was
inactive. This makes DB[a,l]P the most potent non-methylated PAH evaluated
to date in C3H10T1/2 cells. DNA adducts of DB[a,l]P in C3H10T1/2 cells were
analyzed by both TLC and TLC/HPLC 32P-postlabeling methods using
mononucleotide 3'-phosphate adduct standards derived from the reactions of
anti-DB[a,l]P-11,12-diol- 13,14-epoxide (anti-DB[a,l]PDE) and
syn-DB[a,l]P-11,12-diol-13,14- epoxide (syn-DB[a,l]PDE) with deoxyadenosine
3'-monophosphate and deoxyguanosine 3'-monophosphate. All of the DNA
adducts observed in C3H10T1/2 cells treated with DB[a,l]P were identified
as being derived from the metabolism of DB[a,l]P to its fjord region diol
epoxides through DB[a,l]P-11,12-diol. The predominant adduct was identified
as an anti-DB[a,l]PDE-deoxyadenosine adduct. Other major adducts were anti-
DB[a,l]PDE-deoxyguanosine and syn-DB[a,l]PDE-deoxyadenosine adducts with
minor amounts of syn-DB[a,l]PDE-deoxyguanosine adducts. These DNA adduct
data are consistent with similar findings of DB[a,l]PDE- deoxyadenosine
adducts in mouse skin studies and human mammary cells in culture.
相似文献
34.
Early stage nasopharyngeal carcinoma: radiotherapy dose and time factors in tumor control 总被引:1,自引:0,他引:1
Chang JT; See LC; Liao CT; Chen LH; Leung WM; Chen SW; Chen WC 《Japanese journal of clinical oncology》1998,28(3):207-213
OBJECTIVE: To evaluate radiotherapy dose and length of treatment in the
control of early stage nasopharyngeal carcinoma (NPC) treated with a
combination of external radiotherapy and brachytherapy, MATERIALS &
METHODS: We reviewed the records of 133 patients with early stage
nasopharyngeal carcinoma (stage I or II, AJC/UICC staging system) who
received definitive radiotherapy in Chang Gung Memorial Hospital from 1979
to 1991. The median follow-up time was 7.1 years with a minimum of 2 years.
All patients were treated with megavoltage external radiotherapy to the
nasopharynx area (63-72 Gy) followed by high dose rate intracavitary
brachytherapy (5-16.5 Gy in one to three fractions, spaced 1-2 weeks
apart). The median total dose and time of irradiation was 75 Gy (69.8-81.4
Gy) and 11.6 weeks (7.8-20 weeks) respectively. Survival analysis was used
to examine the effect of several variables on prognosis. RESULTS: The
5-year rates were 86.4% for local control, 84.7% for disease free survival,
88.5% for actuarial survival and 84.2% for overall survival. The treatment
group (combination of time and dose of irradiation) was the most important
prognostic factor according to Cox's proportional hazard model. Patients
receiving radiation at a total dose of < or = 75 Gy completed in < 12
weeks showed the best prognosis. CONCLUSION: Treatment time and total
treatment dose are both important factors in treating early stage NPC.
Decreasing the total radiation time to < 12 weeks and not exceeding a
radiation dose of 75 Gy gave the best results.
相似文献
35.
Changes in Corneal Subbasal Nerve Morphology and Sensitivity During Orthokeratology: Onset of Change
Purpose
To investigate changes in corneal subbasal nerve fiber density and orientation during a 3-month orthokeratology (OK) lens wear period and their relationship with concurrent changes in corneal sensitivity.Methods
Sixteen subjects wore overnight OK lenses for 90 days and were assessed at baseline, Day 30, and Day 90. Nerve images at the corneal apex and temporal mid-periphery were captured from the right eye only using in vivo confocal microscopy and analyzed to calculate nerve fiber density (NFD) and global nerve fiber orientation (GNFO). Corneal sensitivity was measured using the Cochet-Bonnet aesthesiometer at similar corneal locations. Control groups of non-lens (NL) wearing and conventional rigid gas-permeable (GP) lens-wearing subjects were also examined.Results
Significant changes in NFD, GNFO and corneal sensitivity were observed during OK lens wear over the study period. In the central cornea, both NFD and corneal sensitivity decreased by Day 30, with further reductions at Day 90. Reduced NFD was associated with reduced corneal sensitivity. In the mid-peripheral cornea only, GNFO was rotated in a clockwise direction at Day 30, with further rotation at Day 90. Corneal sensitivity reduction plateaued by Day 30. In the GP lens-wearing subjects, only corneal sensitivity decreased by Day 30 at both corneal locations. No changes were observed in the NL control subjects.Conclusions
Alterations in corneal nerve morphology occur rapidly with commencement of OK lens wear and appear to underpin functional sensitivity loss. Nerve fiber orientation can provide a useful index for changes in corneal nerve morphology. 相似文献36.
Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO study) 总被引:5,自引:0,他引:5
Jennifer L. Evans Judith A. Hahn Kimberly Page-Shafer Paula J. Lum Ellen S. Stein Peter J. Davidson Andrew R. Moss 《Journal of urban health》2003,80(1):137-146
Female injection drug users (IDUs) represent a large proportion of persons infected with HIV in the United States, and women
who inject drugs have a high incidence of hepatitis B virus (HBV) and hepatitis C virus (HCV) injection. Therefore, it is
important to understand the role of gender in injection risk behavior and the transmission of blood-borne virus. In 2000–2002,
844 young (<30 years old) IDUs were surveyed in San Francisco. We compared self-reported risk behavior between 584 males and
260 female participants from cross-sectional baseline data. We used logistic regression to determine whether demographic,
structural, and relationship variables explained increased needle borrowing, drug preparation equipment sharing, and being
injected by another IDU among females compared to males. Females were significantly younger than males and were more likely
to engage in needle borrowing, ancillary equipment sharing, and being injected by someone else. Females were more likely than
males to report recent sexual intercourse and to have IDU sex partners. Females and males were not different with respect
to education, race/ethnicity, or housing status. In logistic regression models for borrowing a used needle and sharing drug
preparation equipment, increased risk in females was explained by having an injection partner who was also a sexual partner.
Injecting risk was greater in the young female compared to male IDUs despite equivalent frequency of injecting. Overlapping
sexual and injection partnerships were a key factor in explaining increased injection risk in females. Females were more likely
to be injected by another IDU even after adjusting for years injecting, being in a relationship with another IDU, and other
potential confounders. Interventions to reduce sexual and injection practices that put women at risk of contracting hepatitis
and HIV are needed. 相似文献
37.
Magnetic resonance imaging in neuronal ceroid lipofuscinosis 总被引:1,自引:0,他引:1
B C Machen J P Williams G B Lum P Dyken J N Joslyn M D Harpen P Dotson 《The Journal of computed tomography》1987,11(2):160-166
Neuronal ceroid lipofuscinosis is a group of neurodegenerative disorders characterized by accumulation of lipofuscin and/or ceroid within the tissues of the body. These entities are manifest by visual, intellectual, and motor deterioration as well as recurrent seizures. Computed tomography has been shown to demonstrate changes of cerebral atrophy in more severely affected patients. Seven patients with neuronal ceroid lipofuscinosis were examined with both computed tomography and magnetic resonance imaging, and the results were correlated with the clinical severity of the disorder. Two less severely affected patients had normal results on computed tomography and magnetic resonance imaging studies. Varying degrees of cerebral atrophy were seen in the remaining five patients with both computed tomography and magnetic resonance imaging. Severity of atrophy correlated with the severity of disability in these patients. Abnormal white matter was seen in the two most severely affected patients only with magnetic resonance imaging. Although the findings in patients with neuronal ceroid lipofuscinosis were nonspecific, the increased sensitivity of magnetic resonance imaging for subtle white matter abnormalities over computed tomography may prove helpful in monitoring the progression of this rare disorder. 相似文献
38.
39.
40.
Monoclonal antibody-based targeted therapy has greatly improved treatment options for patients. However, long-term efficacy of such antibodies is limited by resistance mechanisms. New insights into the mechanisms by which tumors evade immune control have driven innovative therapeutic strategies to eliminate cancer by re-directing immune cells to tumors. Advances in protein engineering technology have generated multiple bispecific antibody (BsAb) formats capable of targeting multiple antigens as a single agent. Approval of two BsAb and three check point blocking mAbs represent a paradigm shift in the use of antibody constructs. Since BsAbs can directly target immune cells to tumors, drug resistance and severe adverse effects are much reduced. The wave of next generation “bispecific or multispecific antibodies” has advanced multiple candidates into ongoing clinical trials. In this review, we focus on preclinical and clinical studies in hematological malignancies as well as discuss reasons for the limited success of BsAbs against solid tumors. 相似文献